When you are developing therapies and technologies that have never existed before, we understand that the faster your discoveries can be applied, the faster they can start improving – and in some cases saving – people’s lives.
On the other hand, you may want to delay your investments until more solid scientific data is available, followed by an accelerated path to operational readiness.
Either way, we are known for delivering solutions quickly.
You’ll also find that we at VILS share your sense of urgency. Many of our scientists and engineers know people who have been afflicted by the very same health conditions you are working to create treatments for. We share your passion for your work because it matters to us.
A process-driven approach
Our way of acting on that urgency and that passion is an exercise in pure practicality: We always start with your idea and your process, not with a predetermined facility that we alter to fit.
For example, lead-time and supply-chain issues can be a matter of life or death in autologous therapies. Production flows must be streamlined to minimize the time between obtaining the plasma or blood of sick patients and modifying cells to create the remedy. Then, the remedy must be delivered under temperature-controlled conditions back to the hospital where it can be infused into the patient.
With allogenic therapies, on the other hand, scale-up and production efficiency issues are among the most important.
After a thorough understanding of the work you are doing, our process architects and engineers design solutions to expedite product development and scalability. Over the years, our work with some of the most innovative scientists in the world has resulted in everything from concept design to complete production facilities. Past successes include:
- Engineering the world’s first purpose-built facility for human-induced pluripotent stem cell (iPSC) therapies. (Link to Cellistic case). These therapies offer a ready-to use alternative for expensive, complex autologous therapies with a difficult, time-sensitive supply chain, resulting in improved wellbeing for more people.
- Platforms that address the variability of immunotherapies and scale them for clinical success.
- Deep experience extends to NK cells, alpha-beta T cells, gamma-delta T Cells, macrophages, and related lineages.
Learn more about our project references (ADD LINK) The facilities we build are not just achievements in biomedical innovation; They are testaments to the art and science of rapid, process-based design, which results in projects that are delivered on time, despite often complex regulatory and operational demands. We translate your process into facilities that are lean and operator-friendly because we not only understand your language, we speak it.
And we act fast, focusing on the essential, because we share your sense of urgency. And, like you, we make our home on the cutting edge.